Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGFR‐TKIs and prognostic factors for patients with NSCLC...

詳細記述

書誌詳細

主要な著者:	John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2023-01-01
シリーズ:	Thoracic Cancer
主題:	afatinib erlotinib gefitinib lung cancer uncommon mutation
オンライン･アクセス:	https://doi.org/10.1111/1759-7714.14537
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!